Nabriva Therapeutics PLC – (NBRV) Sees Large Drop in Short Interest

Share on StockTwits

Nabriva Therapeutics PLC – (NASDAQ:NBRV) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 297,238 shares, a decrease of 62.0% from the January 15th total of 782,642 shares. Currently, 0.7% of the shares of the company are short sold. Based on an average daily volume of 302,378 shares, the days-to-cover ratio is currently 1.0 days.

In other news, Director Charles A. Rowland, Jr. bought 53,000 shares of the firm’s stock in a transaction that occurred on Monday, December 24th. The stock was purchased at an average cost of $1.31 per share, with a total value of $69,430.00. Following the transaction, the director now directly owns 53,000 shares in the company, valued at $69,430. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.15% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Nabriva Therapeutics by 4,353.6% during the 2nd quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 54,159 shares during the last quarter. Wedbush Securities Inc. raised its stake in shares of Nabriva Therapeutics by 12.5% during the 4th quarter. Wedbush Securities Inc. now owns 103,550 shares of the biotechnology company’s stock worth $151,000 after buying an additional 11,500 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Nabriva Therapeutics during the 3rd quarter worth approximately $431,000. Clear Harbor Asset Management LLC raised its stake in shares of Nabriva Therapeutics by 1,195.7% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 212,500 shares of the biotechnology company’s stock worth $443,000 after buying an additional 196,100 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Nabriva Therapeutics by 2,128.9% during the 3rd quarter. Renaissance Technologies LLC now owns 285,300 shares of the biotechnology company’s stock worth $770,000 after buying an additional 272,500 shares in the last quarter. 4.76% of the stock is owned by hedge funds and other institutional investors.

Several analysts have commented on the company. Zacks Investment Research downgraded Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. BidaskClub raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Nabriva Therapeutics in a research note on Monday, January 28th. Finally, ValuEngine downgraded Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Nabriva Therapeutics has an average rating of “Buy” and a consensus price target of $9.89.

NBRV opened at $2.03 on Thursday. The company has a quick ratio of 7.35, a current ratio of 7.35 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -0.82 and a beta of 2.27. Nabriva Therapeutics has a 52 week low of $1.12 and a 52 week high of $6.40.

ILLEGAL ACTIVITY NOTICE: “Nabriva Therapeutics PLC – (NBRV) Sees Large Drop in Short Interest” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://weekherald.com/2019/02/14/nabriva-therapeutics-plc-nbrv-sees-large-drop-in-short-interest.html.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Further Reading: What is a stock split?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply